To view this email as a web page, click here.

Cost Effectiveness of CAR T-Cell Therapy Depends on Long-Term Outcomes

Researchers conducted a cost-effectiveness analysis on the two FDA-approved CAR T-cell therapies for diffuse large B-cell lymphoma.

Venetoclax Combo Therapy Shows Promise in Pediatric Patients with R/R AML

Early data on the safety and tolerability of combination venetoclax and cytarabine or cytarabine/idarubicin were presented at ASCO 2019.

IN CASE YOU MISSED IT

Natural Killer Cell Levels Could Influence Immunotherapy Outcomes for Lymphoma

Patients with follicular lymphoma or diffuse large B-cell lymphoma with a low peripheral blood natural killer cell count at baseline had shorter time to progression.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.